Oligoprogressive renal cell carcinoma: What is the role of surgery?
Chiara Re1,2,3, William H J Ince2,4, Leo Bickley5
1Department of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK.
Objective:
To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications.
Methods:
A non-systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and original studies. Additional sources were identified through manual reference screening.
Results:
Oligoprogression in RCC likely arises from clonal evolution dynamics, with spatially confined subclone mutations and microenvironmental niches yielding differential responses to treatment. Complete metastasectomy may offer a survival benefit, spare patients toxic side effects of systemic therapy, and offers the possibility of histopathological and molecular characterisation of residual disease. Surgery is also particularly important in delayed cytoreductive nephrectomy as the site of oligoprogression. However, this must be weighed against non-negligible surgical morbidity and complication rates. International guidelines recognise the role of surgical resection in the metastatic setting but emphasise low evidence levels and careful patient selection requirements.
Conclusion:
Limited evidence derived from the oligometastatic context constrains optimal patient selection and timing strategies in oligoprogressive RCC. Following the establishment of consensus over definitions and research gaps, future research integrating molecular biomarkers, novel imaging tracers, and multicentre collaborative studies will be essential to develop evidence-based surgical management protocols for this increasingly common clinical scenario.
Insights
Oligoprogression in renal cell carcinoma (RCC) may stem from clonal evolution. Surgery can benefit select patients, but evidence for optimal selection and timing in oligoprogressive RCC remains limited.
Area of Science:
- Oncology
- Surgical Oncology
- Genitourinary Cancers
Background:
- Oligoprogression, a pattern of limited disease advancement, presents unique challenges in renal cell carcinoma (RCC) management.
- Understanding the biological underpinnings of oligoprogression is crucial for developing effective treatment strategies.
Purpose of the Study:
- To review the biological mechanisms and patterns of oligoprogression in RCC.
- To evaluate the current role of surgery in managing oligoprogressive RCC.
- To identify research gaps and future directions for evidence-based surgical protocols.
Main Methods:
- A non-systematic literature search of PubMed/MEDLINE was conducted.
- Included were guidelines, reviews, and original studies, supplemented by manual reference screening.
Main Results:
- Oligoprogression in RCC is linked to clonal evolution dynamics and differential treatment responses.
- Complete metastasectomy may improve survival and allow for detailed disease characterization, particularly in delayed cytoreductive nephrectomy.
- Surgical resection in the metastatic setting is recognized by guidelines but requires careful patient selection due to potential morbidity.
Conclusions:
- Limited evidence hinders optimal patient selection and timing for surgical intervention in oligoprogressive RCC.
- Future research needs to address consensus on definitions and research gaps.
- Integrating molecular biomarkers, advanced imaging, and multicenter studies is essential for evidence-based surgical management protocols.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
01:25Urinary Tract Calculi VI: Surgical Management
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...